Bayer, Chattem Sneeze At NAD Decision On Claritin And Nasacort Comparison
This article was originally published in The Tan Sheet
Executive Summary
NAD’s review of Bayer’s Claritin and Claritin-D ads upsets Bayer and challenger Chattem as both appeal the decision to the National Advertising Review Board. Bayer argues it supports the claim nothing “works faster” than Claritin-D, while Chattem says Bayer does not support claiming Claritin-D “starts to work on allergies in 30 minutes.”
You may also be interested in...
Nasacort 24HR Superiority Claims OK Without Head-To-Head Tests – NAD
“Strong scientific consensus with regard to product efficacy” justifies claims that Sanofi’s Nasacort Allergy 24HR is “the most effective OTC medicine for the treatment of nasal allergy symptoms,” NAD determines. Claritin-maker Merck, in its challenge, argued Sanofi needs head-to-head testing to support the claim.
Sanofi’s Allegra Claims Clear NAD Review In Merck’s Second Challenge
The National Advertising Division upholds Sanofi’s claims its Allegra antihistamine is “proven effective even at 8x high pollen levels.”
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.